Contents

Highlights of This Issue 1511

EDITORIAL

1513  A Message from the Editor-in-Chief
Michael B. Kastan

REVIEW

1514  Reovirus: A Targeted Therapeutic—Progress And Potential
Radhashree Maitra, Mohammad H. Ghalib, and Sanjay Goel

ANGIOGENESIS, METASTASIS, AND THE CELLULAR MICROENVIRONMENT

1526  Genomic (In)stability of the Breast Tumor Microenvironment
Seth Rummel, Allyson L. Valente, Jennifer L. Kane, Craig D. Shriver, and Rachel E. Ellsworth

1532  Targeting Tumor Cell Invasion and Dissemination In Vivo by an Aptamer That Inhibits Urokinase-type Plasminogen Activator through a Novel Multifunctional Mechanism
Kenneth A. Botkjaer, Elena I. Deryugina, Daniel M. Dupont, Henrik Gardsvoll, Erin M. Bekes, Cathrine K. Thuesen, Zhou Chen, Michael Ploug, James P. Quigley, and Peter A. Andreasen

1544  MUC1 Drives c-Met–Dependent Migration and Scattering
Teresa M. Horm, Benjamin G. Bitler, Derrick M. Broka, Jeanne M. Louderbough, and Joyce A. Schroeder

1555  PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer
Alexandra Hockla, Erin Miller, Moh'd A. Salameh, John A. Copland, Derek C. Radisky, and Evette S. Radisky

CELL CYCLE, CELL DEATH, AND SENESCENCE

1567  The Role of Bcl-xL in Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia on Human Colon Cancer
Xinxin Song, Seog-Young Kim, and Yong J. Lee

DNA DAMAGE AND CELLULAR STRESS RESPONSES

1580  Alkylation Sensitivity Screens Reveal a Conserved Cross-species Functionome
David Svilar, Madhu Dyavaiah, Ashley R. Brown, Jiang-bo Tang, Jianfeng Li, Peter R. McDonald, Tong Ying Shun, Andrea Braganza, Xiao-hong Wang, Salony Maniar, Claudette M. St Croix, John S. Lazo, Ian F. Pollack, Thomas J. Begley, and Robert W. Sobol

SIGNALING AND REGULATION

1597  Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells
Yanyuan Wu, Charles Ginther, Juri Kim, Nicole Mosher, Seyung Chung, Dennis Slamon, and Jaydutt V. Vadgama

1607  Analysis of mRNA Profiles after MEK1/2 Inhibition in Human Pancreatic Cancer Cell Lines Reveals Pathways Involved in Drug Sensitivity
Stephan Gysin, Jesse Paquette, and Martin McMahon

Acknowledgment to Reviewers
ABOUT THE COVER

Temozolomide is the primary chemotherapy used in the treatment of glioblastoma, but resistance contributes to poor prognosis. A temozolomide/siRNA synthetic lethal screen in a chemotherapy-resistant glioblastoma derived cell line identified many novel genes, including several involved in the response to reactive oxygen species (ROS). Comparison to alkylation screens conducted in *E. coli* and *S. cerevisiae* suggests that alkylation resistance mechanisms are evolutionarily conserved. Using fluorescence-based microscopy, it was found that high-dose temozolomide treatment increases ROS formation in glioma cells, as detected with the superoxide indicator dihydroethidium (DHE). For details, see article by Svilar et al. on page 1580.